Department of Error

Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396: 887–97—In this Article, in the third paragraph of the Results section, the geometric mean titre of IgGs in participants receiving Gam-COVID-Vac should have read 1345, and the geometric mean titres of IgG on day 28 should have read 5382. In tables S3 and S4 of the appendix, the baseline titres for IgG on day 0 should have been 12.5. In table S5 of the appendix, the baseline titres of NtAb should have been 1.250. Author Amir I Tukhvatulin's name was misspelled in the author byline and in the affiliations section. These corrections have been made to the online version as of Jan 7, 2021.